标题
Phase II study of everolimus in metastatic urothelial cancer
作者
关键词
-
出版物
BJU INTERNATIONAL
Volume 112, Issue 4, Pages 462-470
出版商
Wiley
发表日期
2013-04-03
DOI
10.1111/j.1464-410x.2012.11720.x
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Effects of mTOR Inhibitor Everolimus (RAD001) on Bladder Cancer Cells
- (2011) E. Chiong et al. CLINICAL CANCER RESEARCH
- Management of adverse events associated with the use of everolimus in patients with advanced renal cell carcinoma
- (2011) Camillo Porta et al. EUROPEAN JOURNAL OF CANCER
- An international expanded-access programme of everolimus: Addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy
- (2011) Viktor Grünwald et al. EUROPEAN JOURNAL OF CANCER
- Prognostic Factors in Second-Line Treatment of Urothelial Cancers With Gemcitabine and Paclitaxel (German Association of Urological Oncology Trial AB20/99)
- (2011) Günter Niegisch et al. EUROPEAN UROLOGY
- Treatment of Patients With Metastatic Urothelial Cancer “Unfit” for Cisplatin-Based Chemotherapy
- (2011) Matthew D. Galsky et al. JOURNAL OF CLINICAL ONCOLOGY
- Everolimus for Advanced Pancreatic Neuroendocrine Tumors
- (2011) James C. Yao et al. NEW ENGLAND JOURNAL OF MEDICINE
- PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs
- (2011) B Weigelt et al. ONCOGENE
- Hypoxia-inducible factor and mammalian target of rapamycin pathway markers in urothelial carcinoma of the bladder: possible therapeutic implications
- (2010) Satish K. Tickoo et al. BJU INTERNATIONAL
- Cancer Statistics, 2010
- (2010) A. Jemal et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Inhibition of mammalian target of rapamycin as a therapeutic strategy in the management of bladder cancer
- (2010) Jose J. Mansure et al. CANCER BIOLOGY & THERAPY
- Prognostic Factors in Patients With Advanced Transitional Cell Carcinoma of the Urothelial Tract Experiencing Treatment Failure With Platinum-Containing Regimens
- (2010) Joaquim Bellmunt et al. JOURNAL OF CLINICAL ONCOLOGY
- Everolimus for Subependymal Giant-Cell Astrocytomas in Tuberous Sclerosis
- (2010) Darcy A. Krueger et al. NEW ENGLAND JOURNAL OF MEDICINE
- Personalized Cancer Therapy With Selective Kinase Inhibitors: An Emerging Paradigm in Medical Oncology
- (2009) Ultan McDermott et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Trial of Vinflunine Plus Best Supportive Care Compared With Best Supportive Care Alone After a Platinum-Containing Regimen in Patients With Advanced Transitional Cell Carcinoma of the Urothelial Tract
- (2009) Joaquim Bellmunt et al. JOURNAL OF CLINICAL ONCOLOGY
- Bladder cancer in the elderly
- (2009) Shahrokh F. Shariat et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- Advanced bladder cancer: Status of first-line chemotherapy and the search for active agents in the second-line setting
- (2008) David J. Gallagher et al. CANCER
- Genetic Predictors of MEK Dependence in Non-Small Cell Lung Cancer
- (2008) C. A. Pratilas et al. CANCER RESEARCH
- Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial
- (2008) Robert J Motzer et al. LANCET
- Mammalian target of rapamycin inhibition as a therapeutic strategy in the management of urologic malignancies: Figure 1.
- (2008) Jorge A. Garcia et al. MOLECULAR CANCER THERAPEUTICS
- Antitumor Activity of Rapamycin in a Phase I Trial for Patients with Recurrent PTEN-Deficient Glioblastoma
- (2008) Tim F Cloughesy et al. PLOS MEDICINE
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started